Whether overall or PD-L1-positive advanced ESCC patients, the probability of nivolumab or pembrolizumab plus chemotherapy being cost-effective were 0% compared with chemotherapy (13, 31, 36). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.